Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study
- 142 Downloads
Systemic Sclerosis (SSc) is a chronic disease of unknown etiology which affects the vascular system and connective tissue. A wide series of studies showed an increased prevalence of cancer in patients with SSc than the normal population. Prostacyclin (PGI2) is an endogenously produced element that is basically synthesized by arachiodonic acid through prostacyclin synthesis in vascular system endothelial cells. Iloprost is a stable analogue of PGI2 which is used in the treatment of pulmonary arterial hypertension (PAH). In a limited number of animal models, the anti-metastatic activity of PGI2 is observed. Herein, we report iloprost treatment of a 60-year-old-woman with SSc, who lately developed PAH as a complication of her disease and lung adenocarcinoma as a co-incidence simultaneously. These two mortal complications were both treated successfully with inhaled iloprost until her death due to gastrointestinal complications of SSc.
KeywordsLung adenocarcinoma Prostacyclin analogue Inhaled iloprost Anti-metastatic activity Pulmonary arterial hypertension Systemic Sclerosis
- 1.Gilliland BC (2005) Systemic sclerosis and related disorders. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds) Harrison principles of internal medicine, 6th edn. New York, Mc Graw-Hill, pp 1979–1990Google Scholar
- 7.Siau K, Laversuch CJ, Creamer P, O’Rourke KP (2010) Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int. 8. [Epub ahead of print]Google Scholar
- 12.Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenes S, Mayes M (1994) Inrtavenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sklerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199–206PubMedGoogle Scholar
- 19.Schneider MR, Schillinger E, Schirner M, Skuballa W, Stürzebecher S, Witt W (1991) Effects of prostacyclin analogues in in vivo tumour models. Adv Prostaglandin Thromboxane Leukot Res 21:901–908Google Scholar